LAURUSLABS vs PGHL: Stock Comparison

Laurus Labs Limited vs Procter & Gamble Health Limited

Live data: 22 July 2026, 3:01 PM IST • Source: NSE and company filings

Laurus Labs Limited is the larger company by market capitalisation. Procter & Gamble Health Limited shows a lower P/E, a higher ROE and a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Laurus Labs Limited and Procter & Gamble Health Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, LAURUSLABS is more favourable on 1 of 13 scored metrics and PGHL on 12These counts are context-free and are not an overall rating.

Key Differences

Market Cap
LAURUSLABS is the larger company
₹85,251 Cr vs ₹11,172 Cr
P/E Ratio
PGHL has a lower P/E
34.28x vs 96.78x
P/B Ratio
LAURUSLABS has a lower P/B
16.22x vs 21.36x
EPS
PGHL has higher earnings per share
₹196.64 vs ₹16.46
Dividend Yield
PGHL has a higher dividend yield
2.34% vs 0.19%
Revenue Growth (TTM YoY)
PGHL has faster revenue growth
19.1% vs 5.3%
EPS Growth (TTM YoY)
PGHL has faster EPS growth
54.6% vs 19.4%
Qtr Sales Growth
PGHL has stronger quarterly sales growth
19.1% vs 5.31%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricLAURUSLABSPGHL
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricLAURUSLABSPGHL
Live Price₹1,579.5₹6,745.5
Day Change-0.86%-0.5%
Volume10.2 L4,590
52-Week High₹1,600.1₹6,975
52-Week Low₹810.05₹4,707
Distance from 52W High-1.29%-3.29%

Valuation

MetricLAURUSLABSPGHL
Market Cap₹85,251 Cr₹11,172 Cr
P/E Ratio96.78x34.28x
P/B Ratio16.22x21.36x
EPS₹16.46₹196.64
Book Value₹98.16₹316.01
Dividend Yield0.19%2.34%

Growth

MetricLAURUSLABSPGHL
Revenue Growth (TTM YoY)5.3%19.1%
EPS Growth (TTM YoY)19.4%54.6%
Qtr Sales Growth5.31%19.1%
Qtr Profit Growth19.5%54.6%

Profitability & Leverage

MetricLAURUSLABSPGHL
ROE18.3%61.6%
ROCE17.8%83.5%
Net Margin13.76%23.22%
Operating Margin26.2%32.4%
Debt to Equity0.48x0.02x

Shareholding

As of Mar 2026 • change vs previous quarter
MetricLAURUSLABSPGHL
Promoter Holding27.49%0%
FII Holding25.82% 0.7 pp6.33% 0.13 pp
DII Holding13.97% 1.54 pp12.44% 1.23 pp
Public Holding32.71% 0.85 pp29.42% 1.11 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Laurus Labs Limited and Procter & Gamble Health Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.